Gilead (GILD) is to buy Arcellx (ACLX) for USD 7.8bln

Gilead's acquisition of Arcellx for $7.8 billion signals a strategic move into innovative therapies within the biotechnology sector.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

BoE's Taylor says we will be close to CPI target sustainably, weaker forecasts in terms of output gap and joblessness

Domino's Pizza Inc. (DPZ) Q4 2025 (USD): EPS 5.35 (exp. 5.38), Revenue 1.54bln (exp. 1.52bln); Q4 SSS 3.7% (exp. 2.3%)

Gilead (GILD) is to buy Arcellx (ACLX) for USD 7.8bln

Merck (MRK) is said to reorganise its main Pharma unit and form a separate cancer unity, WSJ reports

Newsquawk Daily US Opening News - 23rd February 2026

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal could enhance Gilead's pipeline, especially in treating complex diseases, and may influence sentiment across the biotech space, potentially driving interest in similar biotech equities and affecting valuations in the sector.

Related headlines

The whole workspace, free to try.

Try it free